Pulmonx Corporation  (LUNG)
Other Ticker:  

Pulmonx Corporation

Business Description

Pulmonx Corporation is a globally recognized medical device company that specializes in the development and commercialization of minimally invasive solutions for patients suffering from chronic obstructive pulmonary disease (COPD) and other lung diseases. The company is dedicated to improving the lives of patients by providing innovative and effective treatment options that are less invasive than traditional surgical procedures.

Pulmonx was founded in 1998 by Rodney Perkins and Rodney Brenneman, two pioneers in the field of interventional pulmonology. The company*s headquarters are located in Redwood City, California, and it has additional offices and research facilities across Europe, Asia, and Australia.

The core technology developed by Pulmonx is called Zephyr Endobronchial Valve (EBV) System. This system consists of small, one-way valves that are inserted into the lungs through a minimally invasive bronchoscopic procedure. The valves are designed to redirect airflow to healthier lung regions, which helps to reduce hyperinflation and improve lung function in patients with severe emphysema.

The Zephyr EBV System has been extensively researched and clinically tested in various studies worldwide. It has received regulatory approvals in many countries, including the United States, Europe, China, and Japan. The system has been proven to provide significant benefits to patients, such as improved lung function, exercise tolerance, and quality of life.

Pulmonx also offers a comprehensive suite of products and services to support the successful implementation of its treatments. This includes medical training and education for healthcare professionals, patient selection tools, and ongoing patient monitoring solutions. The company has a dedicated team of experts who work closely with physicians, hospitals, and healthcare systems to ensure optimal patient outcomes.

In addition to its focus on COPD treatment, Pulmonx is actively involved in research and development efforts to explore new applications of its technology. The company is studying the use of the Zephyr EBV System in other lung diseases, such as bronchiectasis and chronic bronchitis. These efforts highlight Pulmonx*s commitment to advancing the field of interventional pulmonology and providing innovative solutions for patients with respiratory diseases.

Pulmonx has received numerous awards and recognition for its contributions to the medical field. The company*s groundbreaking technology and commitment to patient care have earned it a strong reputation among healthcare professionals and patients alike. With a dedicated and passionate team, Pulmonx continues to push the boundaries of medical innovation and improve the lives of individuals suffering from lung diseases worldwide.

View Company Supplier View Company Competition View Company Customers


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com